Literature DB >> 33763856

Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine.

Lauren R Cirrincione1, Kai J Huang2.   

Abstract

The transgender adult population is growing globally, but clinical pharmacology has lagged behind other areas of transgender medicine. Medical care for transgender adults may include long-term testosterone or estrogen treatment to align secondary sex characteristics with gender identity. Clinicians often use drug-drug interaction data from the general adult population to predict medication disposition or safety among transgender adults. However, this approach does not address the complex pharmacodynamic effects of hormone therapy in transgender adults. In this review, we critically examine sex-related and gender-related differences in clinical pharmacology and apply these data to discuss current gaps in transgender medicine.
© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2021        PMID: 33763856     DOI: 10.1002/cpt.2234

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  A Retrospective Analysis of Creatinine-Based Kidney Function With and Without Sex Assigned at Birth Among Transgender Adults.

Authors:  Sarah K Fadich; Alin Kalayjian; Dina N Greene; Lauren R Cirrincione
Journal:  Ann Pharmacother       Date:  2021-10-20       Impact factor: 3.463

2.  Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.

Authors:  Paul Thoueille; Susana Alves Saldanha; Fabian Schaller; Aline Munting; Matthias Cavassini; Dominique Braun; Huldrych F Günthard; Katharina Kusejko; Bernard Surial; Hansjakob Furrer; Andri Rauch; Pilar Ustero; Alexandra Calmy; Marcel Stoeckle; Manuel Battegay; Catia Marzolini; Pascal Andre; Monia Guidi; Thierry Buclin; Laurent A Decosterd
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

3.  Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity.

Authors:  Karthik Venkatakrishnan; Lisa J Benincosa
Journal:  Clin Pharmacol Ther       Date:  2021-09-22       Impact factor: 6.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.